HSCT–Associated Thrombotic Microangiopathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
HSCT TMA syndrome is clinically represented by microangiopathic hemolytic anemia, renal dysfunction, and neurological symptoms. Its occurrence after transplant depends on various factors, including HLA mismatch, conditioning, immunosuppressive regimens, presence of GVHD, and infectious complications. Characteristic histopathological findings include thickened capillary walls, occluded vascular lumens by microthrombi and endothelial separation with swelling and necrosis.
·
The incidence of HSCT-TMA ranges from 0.5% to
76%, with a mortality rate of 60-90% despite treatment.
Thelansis’s “HSCT–Associated
Thrombotic Microangiopathy Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential HSCT–Associated
Thrombotic Microangiopathy treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of HSCT–Associated Thrombotic Microangiopathy across the 8 MM market from the
centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
HSCT–Associated Thrombotic
Microangiopathy Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment